4547.T Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 апр. 2024 @ 09:15):

Stats
Объем за сегодня	94 700.00
Средний объем	94 132.00
Рыночная капитализация	159.36B
EPS	¥0 ( 2024-01-30 )
Дата следующего отчета о доходах	( ¥110.76 ) 2024-05-06
Last Dividend	¥40.00 ( 2023-03-30 )
Next Dividend	¥0 ( N/A )
P/E	13.44
ATR14	¥3.37 (0.09%)

Объем Корреляция

Длинно: 0.07 (neutral)

Кратко: -0.64 (weak negative)

Signal:(49.743) Neutral

Kissei Pharmaceutical Корреляция

10 Самые положительные корреляции

10 Самые отрицательные корреляции

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

Kissei Pharmaceutical Корреляция - Валюта/Сырье

-0.85
( strong negative )

-0.77
( moderate negative )

0.31
( neutral )

-0.88
( strong negative )

-0.34
( neutral )

0.81
( strong )

Kissei Pharmaceutical Финансовые показатели

Annual	2022
Выручка:	¥67.49B
Валовая прибыль:	¥32.38B (47.97 %)
EPS:	¥228.30

FY	2022
Выручка:	¥67.49B
Валовая прибыль:	¥32.38B (47.97 %)
EPS:	¥228.30

FY	2022
Выручка:	¥65.38B
Валовая прибыль:	¥31.24B (47.78 %)
EPS:	¥280.20

FY	2021
Выручка:	¥69.04B
Валовая прибыль:	¥32.72B (47.39 %)
EPS:	¥113.25

Financial Reports:

No articles found.

Kissei Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥40.00 (N/A)	¥0 (N/A)	¥40.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Kissei Pharmaceutical Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.36 - Stable (12.73%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥7.00	2001-03-27
Last Dividend	¥40.00	2023-03-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	46	--
Total Paid Out	¥794.00	--
Avg. Dividend % Per Year	0.00%	--
Score	3.68	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	4.36
Div. Directional Score	7.40	--

Next Divdend (Est)
(2024-07-03)

¥0 Estimate 1.26 %

Dividend Stability

0.10 Bad

Dividend Score

3.68

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
9434.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
8086.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
7416.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
6632.T	Ex Dividend Knight	2024-03-28	Annually	0.00%
5958.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
4659.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
3896.T	Ex Dividend Junior	2023-09-28	Annually	0.00%
3116.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
2002.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
9997.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.165	1.500	6.69	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0534	1.200	8.22	9.86	[0 - 0.3]
returnOnEquityTTM	0.0620	1.500	-0.422	-0.634	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	5.93	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	4.22	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	1.155	1.500	4.69	7.04	[0.2 - 2]
debtRatioTTM	0.00608	-1.500	9.90	-10.00	[0 - 0.6]
interestCoverageTTM	141.28	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	186.97	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	186.97	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.00707	-1.500	9.97	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.482	1.000	5.29	5.29	[0.2 - 0.8]
operatingProfitMarginTTM	0.0345	1.000	-1.310	-1.310	[0.1 - 0.6]
cashFlowToDebtRatioTTM	6.04	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.323	0.800	-1.182	-0.946	[0.5 - 2]
Total Score				10.43

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	13.21	1.000	8.77	0	[1 - 100]
returnOnEquityTTM	0.0620	2.50	-0.272	-0.634	[0.1 - 1.5]
freeCashFlowPerShareTTM	186.97	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	2.29	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	186.97	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.0896	1.500	-2.74	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.114	1.000	9.65	0	[0.1 - 0.5]
Total Score				4.36

Kissei Pharmaceutical

Kissei Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products primarily in Japan. It offers Urief and Urief OD tablets for the treatment of dysuria; Glufast, Glubes, and Marizev tablets for type 2 diabetes; Darbepoetin Alfa BS and Epoetin Alfa BS injections for the treatment of renal anemia; Beova tablets for overactive bladder treatment; P-TOL chewable tablets for treating hyperphosphatemia; and Minirin Melt OD tablets for nocturia due to nocturnal polyuria in males, central diabetes insipidus, and nocturnal enuresis resulted from decrease of urine osmolality. The company's products in pipeline include KPS-0373 that has completed Phase III clinical trial to treat spinocerebellar ataxia; CCX168, which has completed Phase III clinical trial for the treatment of microscopic polyangiitis and granulomatosis with polyangiitis; AJM300, which is in Phase III clinical trial to treat ulcerative colitis; R788 that is in Phase III clinical trial to treat chronic idiopathic thrombocytopenic purpura; and MR13A9, which is in Phase III clinical trial to treat uremic pruritus in dialysis patients. It is also developing KLH-2109 for treating endometriosis and uterine fibroids; KDT-3594 for the treatment of Parkinson's disease; Silodosin for dysuria associated with benign prostatic hyperplasia; Mitiglinide for type 2 diabetes mellitus; and Bedoradrine for the treatment of acute exacerbation of asthma. In addition, it develops and sells protein controlled and energy supply foods; and purchases and sells related materials, as well as offers system development and information processing, construction contracting, equipment and facility management, and information gathering and development support services. The company was formerly known as Kissei Yakuhin Kogyo Co., Ltd. and changed its name to Kissei Pharmaceutical Co., Ltd. in October 1964. The company was founded in 1946 and is headquartered in Matsumoto, Japan.